Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec

This article was originally published in The Pink Sheet Daily

Executive Summary

An R&D overhaul trimmed 17 candidates from pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.

You may also be interested in...



Energized Biogen Idec On Track For Two Filings In 2012

Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Unilever Hit With Class Action Over Mercury-Laced Pond’s Cream Originating In Mexico

According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel